Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 2

2(33.3%)

Phase 3

1(16.7%)

6Total

N/A(3)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06595290Not ApplicableRecruiting

Vietnamese Rapid Acceleration Protocol for Intensifying Drug Therapy in Heart Failure With Reduced Ejection Fraction

Role: collaborator

NCT04325035Phase 2Completed

The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

Role: collaborator

NCT05865665Not Yet Recruiting

Registry Of Best Up-titration STrategies in Acute Heart Failure

Role: collaborator

NCT04235062Not ApplicableCompleted

NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure

Role: lead

NCT03412201Not ApplicableUnknown

Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testinG, of Heart Failure Therapies

Role: collaborator

NCT01822808Phase 3Unknown

Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure

Role: collaborator

NCT00699712Phase 2Completed

Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF)

Role: collaborator

All 7 trials loaded